SFX by Ex Libris Inc.

Title:	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease
Source:	Cell Research [1001-0602] Cutri, Belinda yr:2006

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Brown, M. "Biomedicine. Lowering LDL--not only how low, but how long?" Science 311.5768 (2006): 1721-3.
description	2.	Cohen, Jonathan C C. "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease." The New England journal of medicine 354.12 (2006): 1264-72.
description	3.	Tall, Alan R., A. "Protease Variants, LDL, and Coronary Heart Disease." The New England journal of medicine 354.12: 1310-2.
description	4.	Brown, M S S. "Heart attacks: gone with the century?" Science 272.5262 (1996): 629-629.
description	5.	Peterson, Stephen G S. "PCSK9 function and physiology." Journal of lipid research 49.7 (2008): 1595-9.
description	6.	Goldstein, J L L. "Regulation of the mevalonate pathway." Nature 343.6257: 425-430.
description	7.	Kotowski, K. "A Spectrum of PCSK9 Alleles Contributes to Plasma levels of Low-Density lipoprotein Cholesterol." American journal of human genetics 78.3 (2006): 410-22.
description	8.	Sabatine, Marc S. "Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease." The New England Journal of Medicine 376.18 (2017): 1713-1722.
description	9.	Horton, Jay D. "Molecular biology of PCSK9: its role in LDL metabolism." Trends in biochemical sciences 32.2 (2007): 71-7.
description	10.	Lifton, R P P. "Molecular mechanisms of human hypertension." Cell 104.4 (2001): 545-556.
description	11.	Rauthan, M. "The mevalonate pathway in C. Elegans." Lipids in Health and Disease 10.1 (2011): 243-243.
description	12.	Kita, T. "Role of oxidized LDL in atherosclerosis." Annals of the New York Academy of Sciences 947.ATHEROSCLEROSIS VI: THE SIXTH SARATOGA INTERNATIONAL CONFERENCE (2001): 199-206.
description	13.	Sun, Li-Ping P. "Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro." The Journal of biological chemistry 280.28 (2005): 26483-90.
description	14.	Kwon, H. "Molecular basis for LDL receptor recognition by PCSK9." Proceedings of the National Academy of Sciences of the United States of America 105.6 (2008): 1820-1825.
description	15.	Schmidt, H. "Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome." Intensive care medicine 32.8 (2006): 1248-1251.
description	16.	Lin, R A A. "Synthesis and in vitro biological activity of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha,12 alpha-diol, a 12alpha-hydroxyl analog of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha-ol: the latter is a potent activator of the low-density lipoprotein r." Steroids 64.10 (1999): 735-41.
description	17.	Holla, Øystein L L. "Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly." BMC cell biology 8 (2007): 9-.
description	18.	Goldstein, J.L. L. "Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia." The Journal of biological chemistry 249.16 (1974): 5153-5162.
description	19.	Martin, Vincent J J J. "Engineering a mevalonate pathway in Escherichia coli for production of terpenoids." Nature biotechnology 21.7 (2003): 796-802.
description	20.	Timmerman, Gayle M. "Restaurant eating in nonpurge binge-eating women." Western journal of nursing research 28.7 (2006): 811-824.